SCHEDULE: T. Rowe Price Discloses Stake in Replimune Group

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 0.2% of Replimune Group Inc.'s common stock as of April 30, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G amendment, indicating their beneficial ownership of Replimune Group Inc. common stock.
• As of April 30, 2026, T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune Group Inc. common stock.
• This represents approximately 0.2% of the total class of securities.
• The filing indicates sole voting power over 152,716 shares and sole dispositive power over 157,965 shares.
• T. Rowe Price Associates, Inc. certifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing; it's a routine ownership disclosure by a large asset manager and does not contain new operational or financial information about Replimune Group Inc.

Positives

• T. Rowe Price Associates, Inc. maintains a beneficial ownership stake, suggesting continued interest in Replimune Group Inc.
• The filing confirms that the shares are held in the ordinary course of business, implying a standard investment approach.

Negatives

• The reported ownership stake of 0.2% is relatively small, indicating a passive investment rather than a significant controlling interest.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.

Future Outlook

No specific future outlook or guidance is provided in this Schedule 13G filing, as it pertains to ownership disclosure.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. T. Rowe Price Associates, Inc. is a major global asset management firm, and their filings often indicate significant investment activity across various sectors, including biotechnology where Replimune Group Inc. operates.

Stakeholder Impact

• Shareholders: The filing provides transparency on institutional ownership, which can be a factor in investment decisions, but the small percentage suggests minimal immediate impact on share price or control.

Next Steps

• No specific next steps are outlined in this filing beyond the standard reporting requirements.

Key Dates

Keywords

Replimune Group Inc, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing